MCID: PRS004
MIFTS: 32

Prostate Squamous Cell Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Squamous Cell Carcinoma

MalaCards integrated aliases for Prostate Squamous Cell Carcinoma:

Name: Prostate Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Prostate 12 69
Squamous Cell Carcinoma of the Prostate 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10287
NCIt 47 C5536
SNOMED-CT 64 399590005
UMLS 69 C1302530

Summaries for Prostate Squamous Cell Carcinoma

MalaCards based summary : Prostate Squamous Cell Carcinoma, also known as squamous cell carcinoma of prostate, is related to hypersecretion glaucoma and congenital hemolytic anemia. An important gene associated with Prostate Squamous Cell Carcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Cytoskeletal Signaling and Keratinization. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and liver, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Related Diseases for Prostate Squamous Cell Carcinoma

Diseases related to Prostate Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
id Related Disease Score Top Affiliating Genes
1 hypersecretion glaucoma 10.6 KLK3 SMUG1
2 congenital hemolytic anemia 10.6 KRT5 KRT8
3 raynaud disease 10.6 KLK3 SMUG1
4 olivopontocerebellar atrophy deafness 10.5 KRT5 KRT8
5 cribriform carcinoma 10.5 KRT5 KRT8
6 adult fibrosarcoma 10.5 CEACAM5 KLK3
7 pulmonary vein leiomyosarcoma 10.5 CEACAM5 KLK3
8 fallopian tube transitional cell carcinoma 10.5 KRT5 SMUG1
9 sphenoid sinus squamous cell carcinoma 10.5 CEACAM5 KLK3
10 breast adenomyoepithelial adenosis 10.4 CEACAM5 KLK3
11 urethral villous adenoma 10.4 CEACAM5 KLK3
12 penis squamous cell carcinoma 10.4 CEACAM5 KRT5
13 arteriolosclerosis 10.4 KRT5 SMUG1
14 intestine carcinoma in situ 10.4 CEACAM5 SMUG1
15 ductal carcinoma in situ 10.4 KRT5 KRT8
16 ureter squamous cell carcinoma 10.4 CEACAM5 SMUG1
17 monieziasis 10.4 CEACAM5 SMUG1
18 familial lipoprotein lipase deficiency 10.4 KRT5 SMUG1
19 ocular motility disease 10.4 CEACAM5 SMUG1
20 pineal region meningioma 10.4 CEACAM5 SMUG1
21 vulva adenocarcinoma 10.4 KRT5 KRT8
22 brain stem glioma 10.3 CEACAM5 SMUG1
23 gerstmann syndrome 10.3 CEACAM5 SMUG1
24 sebaceous adenocarcinoma 10.3 KRT5 KRT8
25 polyarteritis nodosa 10.3 CEACAM5 SMUG1
26 traumatic brain injury 10.3 CEACAM5 SMUG1
27 lacrimal gland mucoepidermoid carcinoma 10.3 CEACAM5 KRT5
28 transient neonatal thrombocytopenia 10.3 CEACAM5 SMUG1
29 adrenal gland disease 10.2 B2M SMUG1
30 steroid-induced glaucoma - borderline 10.2 KLK3 KRT7
31 thrombotic thrombocytopenic purpura 10.2 B2M HLA-A
32 prostaglandin-endoperoxide synthase deficiency 10.2 KRT7 KRT8
33 engraftment syndrome 10.2 KRT7 KRT8
34 cerebellar vermis medulloblastoma 10.2 KLK3 KRT7
35 cervical adenitis 10.1 KRT5 KRT7
36 endometrial disease 10.1 KRT5 KRT7
37 fibular collateral ligament bursitis 10.1 KLK3 KRT7
38 acantholytic acanthoma 10.1 KRT5 KRT7
39 malignant biphasic mesothelioma 10.1 KRT7 KRT8
40 uterine benign neoplasm 10.1 KRT7 KRT8
41 urethra clear cell adenocarcinoma 10.1 CEACAM5 KRT5 KRT8
42 rectum lymphoma 10.1 KRT7 KRT8
43 diffuse pulmonary fibrosis 10.1 KRT5 KRT7
44 coronary aneurysm 10.1 KRT7 SMUG1
45 classic variant of chromophobe renal cell carcinoma 10.1 KRT7 KRT8
46 vaginal adenoma 10.1 KRT5 KRT7
47 ovarian melanoma 10.0 KRT7 SMUG1
48 chronic inflammatory demyelinating polyradiculoneuropathy 10.0 B2M KLK3
49 mediastinum synovial sarcoma 10.0 KRT5 KRT7
50 plasmodium ovale malaria 10.0 KRT5 KRT7

Graphical network of the top 20 diseases related to Prostate Squamous Cell Carcinoma:



Diseases related to Prostate Squamous Cell Carcinoma

Symptoms & Phenotypes for Prostate Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 KRT5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.77 KRT5 KRT8
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.77 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.77 KRT8
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 KRT7
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.77 KRT5 KRT7 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.77 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.77 KRT5 KRT7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.55 HLA-A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.55 HLA-A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.55 HLA-A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.55 KRT8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.55 KRT7 KRT8
15 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.55 HLA-A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.55 HLA-A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.55 HLA-A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.55 KRT7 KRT8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.55 HLA-A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.55 KRT8
21 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.55 HLA-A
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.55 HLA-A KRT7 KRT8

Drugs & Therapeutics for Prostate Squamous Cell Carcinoma

Drugs for Prostate Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
4 Liver Extracts Phase 3,Phase 1
5 Adjuvants, Anesthesia Phase 3
6 Analgesics Phase 3
7 Analgesics, Opioid Phase 3
8 Anesthetics Phase 3
9 Anesthetics, General Phase 3
10 Anesthetics, Intravenous Phase 3
11 Central Nervous System Depressants Phase 3
12 Narcotics Phase 3
13 Peripheral Nervous System Agents Phase 3
14 Antimitotic Agents Phase 3,Phase 1,Early Phase 1
15 Cola Nutraceutical Phase 3,Phase 1,Phase 2
16
Everolimus Approved Phase 2 159351-69-6 6442177
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
19
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
20 Immunosuppressive Agents Phase 2,Phase 1
21 Androgens Phase 1, Phase 2
22 Anti-Infective Agents Phase 1, Phase 2
23 Antiviral Agents Phase 1, Phase 2,Early Phase 1
24 Antibodies Phase 1, Phase 2
25 Antibodies, Monoclonal Phase 1, Phase 2
26 Carboxymethylcellulose Sodium Phase 1, Phase 2
27 Cathartics Phase 1, Phase 2
28 Gastrointestinal Agents Phase 1, Phase 2
29 Immunoglobulins Phase 1, Phase 2
30 Interferon Inducers Phase 1, Phase 2
31 interferons Phase 1, Phase 2
32 Laxatives Phase 1, Phase 2
33 Poly I-C Phase 1, Phase 2
34 Poly ICLC Phase 1, Phase 2
35 Vaccines Phase 1, Phase 2
36 Thromboplastin Phase 1, Phase 2
37 Anti-Bacterial Agents Phase 2,Early Phase 1
38 Antibiotics, Antitubercular Phase 2
39 Antifungal Agents Phase 2
40
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
41
Paclitaxel Approved, Vet_approved Phase 1,Early Phase 1 33069-62-4 36314
42
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
43
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
44
Gemcitabine Approved Phase 1 95058-81-4 60750
45
Lenograstim Approved Phase 1 135968-09-1
46
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
47
Mechlorethamine Approved Phase 1 51-75-2 4033
48
7-hydroxystaurosporine Experimental Phase 1 112953-11-4 72271
49
Camptothecin Experimental Phase 1 7689-03-4
50 Staurosporine Experimental Phase 1 62996-74-1

Interventional clinical trials:

(show all 40)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
3 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck Completed NCT01059643 Phase 2 LY2523355;pegfilgrastim
4 Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT00605618 Phase 1, Phase 2 BMS-777607
5 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
6 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
7 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Active, not recruiting NCT02001623 Phase 1, Phase 2 Tisotumab Vedotin (HuMax-TF-ADC)
8 Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Active, not recruiting NCT02646319 Phase 2 Nanoparticle Albumin-Bound Rapamycin
9 A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer Terminated NCT02042885 Phase 1, Phase 2 OPB-111001
10 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
11 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
12 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
13 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
14 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
15 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
16 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
17 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
18 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
19 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Recruiting NCT01772004 Phase 1 Avelumab
20 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Recruiting NCT03098160 Phase 1 Evofosfamide;Ipilimumab
21 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting NCT03076372 Phase 1 MM-310
22 Safety Study of MGA271 in Refractory Cancer Recruiting NCT01391143 Phase 1
23 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting NCT02628535 Phase 1
24 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting NCT01353625 Phase 1 CC-115
25 Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer Suspended NCT00909558 Phase 1
26 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
27 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
28 A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer Completed NCT01614002
29 The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer Completed NCT00605488
30 Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer Completed NCT00364715
31 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
32 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
33 Questionnaire in Screening Older Patients With Cancer Completed NCT00963911
34 Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Completed NCT00002520 nicotine
35 Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma Recruiting NCT02119559
36 GlucoCEST MRI in Oncology Recruiting NCT03212157
37 Autologous Natural Killer T Cells Infusion for the Treatment of Cancer Recruiting NCT01801852
38 A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers Active, not recruiting NCT00122239
39 Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line Not yet recruiting NCT03292822 Early Phase 1 Paclitaxel
40 FACBC for Head and Neck Cancers Suspended NCT01933269 Early Phase 1 FACBC

Search NIH Clinical Center for Prostate Squamous Cell Carcinoma

Genetic Tests for Prostate Squamous Cell Carcinoma

Anatomical Context for Prostate Squamous Cell Carcinoma

MalaCards organs/tissues related to Prostate Squamous Cell Carcinoma:

39
Prostate, Lung, Liver, Breast, T Cells, Kidney, Brain

Publications for Prostate Squamous Cell Carcinoma

Variations for Prostate Squamous Cell Carcinoma

Expression for Prostate Squamous Cell Carcinoma

Search GEO for disease gene expression data for Prostate Squamous Cell Carcinoma.

Pathways for Prostate Squamous Cell Carcinoma

Pathways related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.92 KRT5 KRT7 KRT8
2
Show member pathways
11.79 KRT5 KRT7 KRT8
3
Show member pathways
11.11 B2M HLA-A
4
Show member pathways
10.83 KRT5 KRT7 KRT8
5 10.35 B2M HLA-A

GO Terms for Prostate Squamous Cell Carcinoma

Cellular components related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.43 KRT5 KRT7 KRT8
2 recycling endosome membrane GO:0055038 9.37 B2M HLA-A
3 ER to Golgi transport vesicle membrane GO:0012507 9.32 B2M HLA-A
4 extracellular exosome GO:0070062 9.17 B2M CEACAM5 HLA-A KLK3 KRT5 KRT7
5 MHC class I protein complex GO:0042612 9.16 B2M HLA-A
6 keratin filament GO:0045095 9.13 KRT5 KRT7 KRT8

Biological processes related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.33 KRT5 KRT7 KRT8
2 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.26 B2M HLA-A
3 cornification GO:0070268 9.13 KRT5 KRT7 KRT8
4 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 8.62 B2M HLA-A

Molecular functions related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 scaffold protein binding GO:0097110 8.62 KRT5 KRT8

Sources for Prostate Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....